Global Non-antibiotic Bacterial Therapeutics Industry 2019-2024: Market Dynamics, Technologies and Company Profiles

News provided by

Mar 27, 2019, 06:15 ET

DUBLIN, March 27, 2019 /PRNewswire/ -- The "Global Markets Non-antibiotic Bacterial Therapeutics" report has been added to ResearchAndMarkets.com's offering.

As bacteria grow resistant to conventional antibiotics, alternatives are being investigated, including antibodies, probiotics, bacteriophages, and antimicrobial peptides currently undergoing clinical trials. The specificity of antibodies, and the inability of bacteria to develop resistance against them, make antibodies attractive, albeit expensive, alternative therapeutic agents.

Bacteriophages have been used for therapy in some parts of the world. Antimicrobial peptides have long been considered as potential replacements for antibiotics but with limited success. Synthetic peptides and synthetic Antibiotic membrane-active agents might herald a shift.

What You Will Learn

What are the classes of non-antibiotics drugs that can treat bacterial infections alone or in conjunction with existing antibiotics?
What non-antibiotic bacterial therapies are in late stage development, who are the developers, and what indications are they targeting?
What are the major factors driving demand for non-antibiotic bacterial treatments?
What is the size of the market today, who are the market share leaders, and what will the market share be in 2024?
What are the essential factors, technologies and market development issues for non-antibiotic bacterial therapeutics products?
What are the significant economic, technology, and regulatory factors affecting the market for non-antibiotic Bacterial Therapies?

Key Topics Covered

1. Executive Summary

2. Market Dynamics

The Unmet Need
Defining the Scope
The Evolving Landscape

3. Technology

Antibodies
Antibiotic-deactivating Enzymes
Bacteriophages
Antimicrobial peptides
Antimicrobial Nanoparticles
Antisense therapy/gene silencing
Active extrusion of bacterial compounds/membrane pumps
Overexpression of Multidrug resistance efflux pumps
Siderophores

4. Non-antibiotic Microbial Therapeutics - Therapies

Antibodies
Lysins
Phages
Antimicrobial Peptides
Defensins
Host Directed Therapies

5. Non-antibiotic Bacterial Therapeutics - Primary Targets

Clamydia
Clostridium Difficile
Klebsiella pneumoniae
Pseudomonas aeruginosa
Staphylococcus aureus
Mycobacteria Tubercolosis

6. Private Research

Univ of Hong Kong
Case Western
Boston's Children's Hospital

7. Global Market Regulations and Standards

North America
US FDA
US Centers for Disease Control
Europe
European Centre for Disease Prevention and Control
Asia
Chinese Center for Disease Control and Prevention
National Centre for Disease Control (India)

8. Company Profiles

For more information about this report visit https://www.researchandmarkets.com/research/43cwv6/global?w=5

Media Contact:

Research and Markets
Laura Wood, Senior Manager
[email protected]

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

SOURCE Research and Markets